Why the study?
Enterovirus 71 causes Hand, Foot, and Mouth disease and can be deadly in children and infants, motivating the search for a novel antiviral drug for use after infection.
Does a combination of Mitrofudil and N6-Benzyladenosine reduce ATPase activity in an in vitro Enterovirus 71 2C protein model?
Does a combination of Mitrofudil and N6-Benzyladenosine reduce ATPase activity in an in vitro Enterovirus 71 2C protein model?
A combination of Mitrofudil and N6-Benzyladenosine successfully inhibited the ATPase activity of the EV 71 2C protein in vitro, identifying a potential novel antiviral strategy for Hand, Foot, and Mouth disease.
No takes yet. Share an insight, caveat, or question.
Murali et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: